Bicycle Therapeutics plc (BCYC) Revenue History
Annual and quarterly revenue from 2016 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
Revenue Growth Metrics
BCYC Revenue Analysis (2016–2024)
As of March 1, 2026, Bicycle Therapeutics plc (BCYC) generated trailing twelve-month (TTM) revenue of $28.3 million, reflecting explosive growth of +338.5% year-over-year. The most recent quarter (Q3 2025) recorded $11.7 million in revenue, up 301.8% sequentially.
Looking at the longer-term picture, BCYC's 5-year compound annual growth rate (CAGR) stands at +20.6%, indicating outstanding long-term growth trajectory. The company achieved its highest annual revenue of $35.3 million in 2024, representing a new all-time high.
When compared to Healthcare sector peers including REGN (+1.0% YoY), IMNM (-4.4% YoY), and CLDX (-78.6% YoY), BCYC has outperformed the peer group in terms of revenue growth. Compare BCYC vs REGN →
Peer Comparison
Compare BCYC's revenue metrics with industry peers
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| BCYCCurrent | $28M | +338.5% | +20.6% | -595.0% | |
| REGN | $14.3B | +1.0% | +11.0% | 25.7% | |
| IMNM | $9M | -4.4% | - | -3382.4% | |
| CLDX | $2M | -78.6% | -27.4% | -19160.0% | |
| RXRX | $75M | +27.5% | +85.4% | -867.9% | |
| NRIX | $84M | +54.0% | +36.3% | -340.2% |
Historical Revenue Data
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $35.3M | +30.8% | $-137,691,000 | -390.3% | $-209,872,000 | -595.0% |
| 2023 | $27.0M | +86.5% | $-129,520,000 | -480.1% | $-189,946,000 | -704.1% |
| 2022 | $14.5M | +23.6% | $14.5M | 100.0% | $-116,653,000 | -806.6% |
| 2021 | $11.7M | +12.6% | $11.7M | 100.0% | $-65,618,000 | -561.0% |
| 2020 | $10.4M | -24.7% | $-22,759,000 | -219.0% | $-51,960,000 | -500.1% |
| 2019 | $13.8M | +93.4% | $-11,739,000 | -85.1% | $-26,299,000 | -190.6% |
| 2018 | $7.1M | +246.4% | $-13,625,000 | -190.9% | $-21,746,000 | -304.7% |
| 2017 | $2.1M | - | $-9,806,000 | -476.0% | $-16,213,000 | -787.0% |
| 2016 | $0 | - | $-269,289 | - | $-13,493,410 | - |
See BCYC's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs BCYC Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare BCYC vs AGIO
See how BCYC stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is BCYC's revenue growth accelerating or slowing?
BCYC revenue is accelerating at +338.5% year-over-year, exceeding the 5-year CAGR of +20.6%. TTM revenue reached $28M. Growth momentum has increased versus prior periods.
What is BCYC's long-term revenue growth rate?
Bicycle Therapeutics plc's 5-year revenue CAGR of +20.6% reflects the sustained expansion pattern. Current YoY growth of +338.5% is above this long-term average.
How is BCYC's revenue distributed by segment?
BCYC reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2016-2024 are available for download. Segment mix reveals concentration and diversification trends.